Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Chemoradiation vs Radiotherapy in Low Risk NK/T-cell Lymphoma
NCT01667289Phase 2Terminated
- Sponsor
- Fudan University
- Start
- Jun 2012
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-free survival at 3 years. Started Jun 2012; status: terminated.
02
Drugs
methotrexate
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT01667289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01667289.